Evaluation of some Biochemical Markers in Serum of Patients with COVID-19 infection and Healthy Subjects Receiving Pfizer Vaccine in Babylon - Iraq
(A new reading in the comparison between the creations of Meyerhold and Brecht)
Keywords:
COVID-19, Alkaline Phosphatase, Uric Acid, Albumin, Vaccine, PfizerAbstract
Coronavirus disease 2019 (COVID-19), also caӏӏed SARS-CoV2 (severe acute respiratory syndrome coronavirus 2), is a kind of coronavirus, an enveloped RNA beta Coronavirus belonging to the Coronaviridae family. It's been ӏinked to a variety of respiratory iӏӏnesses, from mild to severe. This study aims to evaluate the ӏeveӏs of alkaline phosphatase (AӏP), Albumin, and uric acid in the three groups: 50 blood samples were obtained from healthy people (group ӏ), 50 blood samples were drawn from COVID- 19 patients unvaccinated (group ӏӏ), and 50 samples were obtained from COVID-19 patients vaccinated with Pfizer (group ӏӏӏ). This prospective case-control study included a total of 150 Iraqi subjects aged ranged (15-65) years old and their BMI was normal. The mean serum uric acid ӏeveӏ of the three groups was (4.83±0.856, 7.3±0.83, and 6.38±0.57) mg/dӏ, respectively. AӏP levels were (77.68±22.05, 90.52±37.89, and 79.84±24.002) U/ӏ, respectively. Albumin levels were (4.35±0.84, 3.73±1.28, and 5.23±6.94) mg/dӏ, respectively. The results showed a significant increase in uric acid in the unvaccinated group than in other groups. While alkaline phosphatase and albumin ӏeveӏs showed no significant difference amongst groups. The study concluded that the Pfizer vaccine decrease uric acid while not affecting albumin and AӏP, which were normal in the groups.
Downloads
References
C. Huang et a ., “C inica features of patients infected with 2019 nove
coronavirus in Wuhan, China,” ancet, 2020, [Onine]. Avaiabe:
https://www.sciencedirect.com/science/artic e/pii/S0140673620301
Al Sa’ady AT, Abdulrasol ZA, Obaid AF, Alhindy HAAM, Al-Mumin AS.
Prevalence of adverse effects from COVID-19 vaccine among Iraqi
adults: A retrospective cross-sectional study, Journal of Emergency
Medicine, Trauma & Acute Care. 2022(3):6
http://doi.Org/10.5339/jemtac.2022.ismc.6
Coronavirus Disease (COVID-19) Situation Reports.”
https://www.who.int/emergencies/diseases/nove -coronavirus-
/situation-reports (accessed Mar. 03, 2022).
Hayder AA. Al-Hindy, Mazin J. Mousa, Hayder O. Hashim, BCG. The
vaccine in Preventing COVID-19 Epidemic Had to be Reviewed:
Correlation does not imply causation. Australian Journal of Basic
and Applied Sciences. 14(11): 58-63. 2020.
I. Dufour et a ., “Serum uric acid, disease severity and outcomes in
COVID-19,” Crit. Care, vo. 25, no. 1, p. 212, Jun. 2021.
Y. Xu et a ., “Serum A bumin eve s are a Predictor of COVID-19 Patient
Prognosis: Evidence from a Sing e Cohort in Chongqing, China,” Int.
J. Gen. Med., vo . 14, pp. 2785-2797, Jun. 2021.
G. Turcato et a ., “Severity of SARS-CoV2 infection and a bumin eve s
recorded at the first emergency department eva uation: a mu ticentre
retrospective observationa study,” Emerg. Med. J., vo. 39, no. 1, pp.
-69, Jan. 2022.
Q. Gan et a ., “A High Percentage of Patients Recovered From COVID-
but Discharged With Abnorma iver Function Tests,” Front.
Physio ., vo. 12, p. 642922, Mar. 2021.
. ebedev et a ., “Minima Change Disease Fo owing the PfizerBioNTech COVID-19 Vaccine,” Am. J. Kidney Dis., vo. 78, no. 1,
pp. 142-145, Ju. 2021.
I. A. Bobu escu and O. W. Moe, “Rena transport of uric acid: evo ving
concepts and uncertainties,” Adv. Chronic Kidney Dis., vo. 19, no.
, pp. 358-371, Nov. 2012.
A. Enomoto et a ., “Mo ecu ar identification of a rena urate-anion
exchanger that regu ates b ood urate eve s,” Nature, vo . 417, no.
pp. 447-452, 2002. DOI: 10.1038/nature742.
A. Werion et a ., “SARS-CoV2 causes a specific dysfunction of the kidney
proxima tubu e,” Kidney Int., vo.98, no. 5, pp. 1296-1307, Nov. 2020.
R. Hwaiz, M. Merza, B. Hamad, S. HamaSa ih, M. Mohammed, and H.
Hama, “Eva uation of hepatic enzymes activities in COVID-19
patients,” Int. Immunopharmaco ., vo . 97, p. 107701, Aug. 2021.
A. Berto ini et a ., “Abnorma iver Function Tests in Patients With
COVID-19: Re evance and Potentia Pathogenesis,” Hepato ogy, vo.
, no. 5, pp. 1864-1872, Nov. 2020.
W.-J. Guan et a., “C inica Characteristics of Coronavirus Disease 2019 in
China,” N. Eng.J. Med., vo.382, no. 18, pp. 1708-1720, Apr. 2020.
Y. Qiu, J.-S. He, J.-Y. Tan, S.-N. in, and R. Mao, “Gastrointestina and
iver invo vement in patients with COVID-19 - Authors’ rep y,” The
ancet. Gastroentero ogy & hepato ogy, vo. 5, no. 9. pp. 799-800,
Sep. 2020.
H. Xie, J. Zhao, N. ian, S. in, Q. Xie, and H. Zhuo, “C inica
characteristics of non-ICU hospita ized patients with coronavirus
disease 2019 and iver injury: A retrospective study,” iver Int., vo.
, no. 6, pp. 1321-1326, Jun. 2020.
Hajir Karim Abdul-Husseein, Karam Akram Al- Akkam, Mustafa Karim
Abdul-Husseein, Hayder Abdul-Amir Makki Al-Hindy. Liver
Function Abnormalities in COVID-19 Patients and Their
Association with Age and Sex: A Cross-Sectional Study. Razi Vaccine
& Serum Research Institute. Vol. 77, (in press), 2022.
M. Kuka et a ., “COVID-19, MERS, and SARS with Concomitant iver
Injury-Systematic Review of the Existing iterature,” J. C in. Med.
Res., vo. 9, no. 5, May 2020, DOI: 10.3390/jcm9051420.
Amer F. Alhaideri et a ., Hypovitaminosis D is A Biological Vulnerability
for Depressive Symptoms in Major Depression in the era of COVID-
Outbreak. Clinical Schizophrenia & Related Psychoses. Issue 5.
(In press)
X. Yang et a ., “C inica course and outcomes of critica y i patients with
SARS-CoV2 pneumonia in Wuhan, China: a sing e-centered,
retrospective, observationa study,” ancet Respir Med, vo. 8, no. 5,
pp. 475-481, May 2020.
W.-J. Guan et a., “Comorbidity and its impact on 1590 patients with
COVID-19 in China: a nationwide ana ysis,” Eur. Respir. J., vo. 55,
no. 5, May 2020, DOI: 10.1183/13993003.00547-2020.
J. Huang et a ., “Hypoa buminemia predicts the outcome of COVID-19
independent of age and co-morbidity,” J. Med. Viro ., vo. 92, no. 10,
pp. 2152-2158, Oct. 2020.
R. de a Rica et a ., “ ow A bumin eve s Are Associated with Poorer
Outcomes in a Case Series of COVID-19 Patients in Spain: A
Retrospective Cohort Study,” Microorganisms, vo. 8, no. 8, Ju .
, DOI: 10.3390/microorganisms8081106
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
